DelveInsight has launched a new report on Cytokine Release Syndrome Market
Cytokine release syndrome (CRS) is a systemic inflammatory response with outpouring of the inflammatory cytokines due to stimulus triggered by a variety of factors such as infections, immunotherapy, especially those involving T-cell engagers and certain other drugs. Even though cytokines acts to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with a number of body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.
Request for free sample copy- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market
The Cytokine Release Syndrome Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cytokine Release Syndrome Market
Cytokine Release Syndrome Market Disease
The main cytokines implicated in the pathogenesis of CRS include interleukin-6 (IL-6), IL-10, tumour necrosis factor (TNF), IL-1, IL-2, IL-8, interferon (IFN)-γ, monocyte chemo attractant protein 1 (MCP-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and others. CRS clinically manifests when large numbers of lymphocytes (B cells, T cells, and/or natural killer cells) and/or myeloid cells (macrophages, dendritic cells, and monocytes) become activated and release inflammatory cytokines.
Cytokine Release Syndrome Symptoms
The most widely used grading scheme for the severity of CRS was developed by the National Cancer Institute (NCI). CRS can be classified into following grades:
Cytokine Release Syndrome Companies
Cytokine Release Syndrome Drugs
Cytokine Release Syndrome Treatment Market
Various incurable malignancies has been managed with cutting edge immunotherapies such as CAR T-cell therapy and specific antibody-based immune engagers. However, the toxicities of these innovative new therapies, especially CRS and neurotoxicity, must be managed. CRS generally occurs within days after CART cell infusion. While identification of factors predictive of severe CRS continues to evolve, one mainstay of CRS treatment is to deploy anti-cytokine therapy early in the CRS course to prevent progression into severe life-threatening higher grade CRS. As many symptoms of CRS can mimic other medical conditions such as sepsis, infection, or adrenal insufficiency, it is of utmost importance that a thorough workup is performed to rule them out.
Cytokine Release Syndrome Report Scope
Table of content
1. Key Insights
2. Executive Summary of Cytokine Release Syndrome (CRS)
3. Cytokine Release Syndrome (CRS) Market Overview at a Glance
4. Disease Background and Overview: Cytokine Release Syndrome (CRS)
5. Case Reports
6. Epidemiology and Patient Population
7. United States Epidemiology
8. EU5 Epidemiology
9. Japan Epidemiology
10. Current Treatment and Medical Practices
11. Unmet needs
12. Marketed Drugs
13. Emerging Drugs
14. Cytokine Release Syndrome (CRS): 7MM Market Analysis
15. Conjoint Analysis
16. United States
17. EU-5 Countries: Market Outlook
18. Japan Market Outlook
19. Market Drivers
20. Market Barriers
21. SWOT Analysis
22. Reimbursement and market access
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Reasons to buy
Related Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/